Experimental Pancreatic Cancer Vaccine Activates Immune Response in Phase 2 Trial

An experimental vaccine for pancreatic cancer has successfully triggered an immune system response in nearly all patients evaluated during a phase 2 clinical trial, according to research published in the scientific journal Nature Medicine. The randomized trial, led by researchers at Mayo Clinic, investigated the immunotherapy approach in patients who had already undergone surgery and chemotherapy for pancreatic tumors featuring specific genetic mutations.

The vaccine, known as camupepimut, targets seven common mutations in the KRAS gene. These mutations are found in approximately 90% of pancreatic ductal adenocarcinomas, which represent the most frequent form of pancreatic cancer. The genetic alterations help cancer cells grow and survive, presenting a major obstacle in oncology because pancreatic tumors have historically proven very difficult to treat with immunotherapy.

The study involved 144 patients with stage 1 through 3 pancreatic cancer carrying the KRAS mutation. Following standard surgical resection and chemotherapy, participants had no visible cancer remaining on imaging scans. Researchers then randomly assigned 96 patients to receive the experimental vaccine and 48 patients to an observation group. Out of the 96 vaccinated individuals, 90 could be evaluated for their immunological reaction.

The findings revealed that 89 of those 90 patients—representing 98.9%—developed increased T-cell activity directed against the mutated KRAS gene. Furthermore, more than 80% of the evaluated participants showed a T-cell response that was at least nine times stronger than their baseline levels before receiving the immunization. Ben George, a clinical oncologist at Mayo Clinic and the lead author of the study, noted that generating such a robust immune response in nearly every evaluated patient is an encouraging development.

Despite the strong cellular immune response, the clinical trial did not meet its primary endpoint of demonstrating a statistically significant improvement in disease-free survival across the entire study population. The median disease-free survival period was 23.8 months for patients who received the vaccine compared to 21.2 months for the observation group. Researchers emphasized that stimulating the immune system does not automatically guarantee that cancer recurrence will be prevented.

However, exploratory analyses revealed promising signals that will guide future research. Patients who exhibited stronger immune responses tended to remain free of the disease for longer periods. Additionally, researchers observed potential links involving circulating tumor DNA and previous radiation therapy, which may help identify which patients are most likely to benefit from the treatment.

The research team plans to advance the investigation with a phase 3 clinical trial to determine whether the vaccine can successfully delay or prevent the recurrence of pancreatic cancer and ultimately improve overall survival rates. Longer follow-up and larger studies will be essential to confirm these clinical outcomes.